Teva today announced the launch of their generic version of Mylan’s EpiPen epinephrine auto-injector. The new entrant comes to market at a time when EpiPen has been experiencing shortages due to manufacturing difficulties by its manufacturing partner Pfizer, leaving many scrambling for an alternative.
The Israeli pharmaceutical company said the adult 0.3mg device is now available in limited supply in the US. Additional supply, as well as their generic version of the EpiPen Jr 0.15mg device, will be available in the new year.
Brendan O’Grady, EVP and Head of North America Commercial at Teva said, “We’re pleased to provide access to Epinephrine Injection (Auto-Injector) for patients who may experience life-threatening allergic emergencies and we’re fully dedicated toward ensuring additional supply in 2019.”